AxoGen Inc
NASDAQ:AXGN
AxoGen Inc
Stock-Based Compensation
AxoGen Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
AxoGen Inc
NASDAQ:AXGN
|
Stock-Based Compensation
$30.1m
|
CAGR 3-Years
25%
|
CAGR 5-Years
29%
|
CAGR 10-Years
37%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Stock-Based Compensation
$299m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Stock-Based Compensation
$158.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Stryker Corp
NYSE:SYK
|
Stock-Based Compensation
$243m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Stock-Based Compensation
$664m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Stock-Based Compensation
$788.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
AxoGen Inc
Glance View
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
See Also
What is AxoGen Inc's Stock-Based Compensation?
Stock-Based Compensation
30.1m
USD
Based on the financial report for Dec 31, 2025, AxoGen Inc's Stock-Based Compensation amounts to 30.1m USD.
What is AxoGen Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
37%
Over the last year, the Stock-Based Compensation growth was 89%. The average annual Stock-Based Compensation growth rates for AxoGen Inc have been 25% over the past three years , 29% over the past five years , and 37% over the past ten years .